Novel Treatments for Neurodegenerative Conditions

NeuroBo Pharmaceuticals is addressing unmet needs in patients with diabetic neuropathy and Alzheimer’s disease.

Our Phase III drug, NB-01, is derived from natural sources and has shown successful Phase II results with excellent efficacy and safety in diabetic neuropathic pain (DNP) and we have strong preclinical data in both neuropathic pain and diabetes models showing a mode of action of NB-01 on nerve growth factor (NGF) release for nerve stabilization and regeneration.

40 to 50 percent of patients with diabetic peripheral neuropathy have some form of neuropathic pain and while existing drugs alleviate pain symptoms, they do not address the underlying disease. These current therapies also have a range of adverse effects, and only about 50 percent of patients respond positively. Additionally, the current therapies on the market were all initially approved for other disease states such as depression and fibromyalgia.

NB-02, our lead Alzheimer’s drug, is in IND-enabling stage and has been extensively characterized in rodent models for mechanisms impacting Alzheimer’s disease (inhibition of AChE, pTau, amyloid-β, and stimulation of NGF for nerve growth.

An aging population has resulted in an increase in the prevalence of Alzheimer’s disease, and the disease is a significant healthcare burden. Today, there are four approved drugs that manage the symptoms of Alzheimer’s disease, yet none of these four address disease modification.


Intellectual property

NB-01 –FTO Completed; no significant risk

Additional filings underway in pain indications

Family I: October 2026 (non-US) and May 2027 (US)

  • Title: Extract of the Family Dioscoreaceae and Composition for Preventing or Treating Peripheral Neuropathy Comprising the Same

  • Method of treatment

Family II: December 2031 

  • Title: Composition Comprising the Extract of Herbs for Preventing or Treating Neurodegenerative Disorders

  • Composition of extract for treatment of neurodegenerative disorders

Family III: December 2031 (diabetic neuropathy)

Protection beyond 2031

  • Composition Comprising the Extract of Herbal Combination for Preventing or Treating Diabetic Peripheral Neuropathy

  • Pending claims

NB-02 – FTO completed; no significant risk

Family I: December 2035 (Neurodegenerative disease treatment using Species I)

  • Title: Composition Containing Poria cocos Peel Extract for Treating Neurodegenerative Disorders

  • Method of treatment

Family II: December 2035 (Combination of Species I and II)

  • Title: Composition Containing Mixed Extract of Mulberry and Poria cocos Bark for Preventing, Improving or Treating Neurodegenerative Disorders 

  • Composition of extract  for preventing or treating of a degenerative neurological diseas